Biosysen (HKG:1355) is proposing to increase its authorized share capital to HK$100 million divided into 10 billion shares, subject to shareholder approval.
The company will do this by creating an additional 8 billion shares, according to a Wednesday Hong Kong bourse filing.
The move comes to accommodate the potential growth of the company and give it greater flexibility to raise funds in the future.
The company currently has 1.19 billion shares in issue and 806.9 million authorized but unissued.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.